Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Trial to Evaluate Hydrochloride Irinotecan Floxurudine Liposome Injection (LY01616) for the Treatment for Patients with Colorectal Cancer

Next Previous
Trial Profile

A Clinical Trial to Evaluate Hydrochloride Irinotecan Floxurudine Liposome Injection (LY01616) for the Treatment for Patients with Colorectal Cancer

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 25 Jun 2020 New trial record
  • 12 Jun 2020 According to a Luye Pharma Group media release, the Investigational New Drug application is the first in China to cover a combinational liposome treatment, representing a breakthrough for the company in terms of combinational liposome R&D and manufacturing ability.
  • 12 Jun 2020 According to a Luye Pharma Group media release, the clinical trials application for the companys self-developed innovative oncology product, Hydrochloride Irinotecan Floxurudine Liposome Injection (LY01616), has received formal acceptance from the China Center for Drug Evaluation of National Medical Products Administration and will soon enter the clinical trials phase.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top